Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
The Journal of Antimicrobial Chemotherapy
|
December 6, 2012
Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study
Gregory A Eschenauer, Peggy L Carver, Shu-Wen Lin, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
April 12, 2025
The therapeutic impact of maximum chemotherapy possession days during three consecutive months in non-tuberculous mycobacterial lung disease: A real-world experience
Ping-Huai Wang, Yu-Feng Wei, Chia-Jung Liu, et al.
Plos One
|
February 20, 2014
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy
Kuan-Yeh Lee, Shu-Wen Lin, Hsin-Yun Sun, et al.
Scientific Reports
|
November 25, 2017
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
Sung-Hsi Huang, Shu-Wen Lin, Sui-Yuan Chang, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
February 10, 2016
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
Mao-Song Tsai, Sui-Yuan Chang, Shu-Wen Lin, et al.
Journal of the International AIDS Society
|
November 25, 2021
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
Bo-Huang Liou, Chih-Ning Cheng, Ya-Ting Lin, et al.
Journal of Clinical Medicine
|
June 9, 2019
Isoniazid Concentration and <i>NAT2</i> Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI
Meng-Rui Lee, Hung-Ling Huang, Shu-Wen Lin, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
July 18, 2020
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
Wei-Chieh Huang, Chun-Kai Huang, Sung-Hsi Huang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 15, 2021
Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV
Sung-Hsi Huang, Wei-Chieh Huang, Shu-Wen Lin, et al.
Plos One
|
September 12, 2015
Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy
Kuan-Yin Lin, Sih-Han Liao, Wen-Chun Liu, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
The Journal of Antimicrobial Chemotherapy
|
December 6, 2012
Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study
Gregory A Eschenauer, Peggy L Carver, Shu-Wen Lin, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
April 12, 2025
The therapeutic impact of maximum chemotherapy possession days during three consecutive months in non-tuberculous mycobacterial lung disease: A real-world experience
Ping-Huai Wang, Yu-Feng Wei, Chia-Jung Liu, et al.
Plos One
|
February 20, 2014
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy
Kuan-Yeh Lee, Shu-Wen Lin, Hsin-Yun Sun, et al.
Scientific Reports
|
November 25, 2017
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
Sung-Hsi Huang, Shu-Wen Lin, Sui-Yuan Chang, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
February 10, 2016
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
Mao-Song Tsai, Sui-Yuan Chang, Shu-Wen Lin, et al.
Journal of the International AIDS Society
|
November 25, 2021
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
Bo-Huang Liou, Chih-Ning Cheng, Ya-Ting Lin, et al.
Journal of Clinical Medicine
|
June 9, 2019
Isoniazid Concentration and <i>NAT2</i> Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI
Meng-Rui Lee, Hung-Ling Huang, Shu-Wen Lin, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
July 18, 2020
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
Wei-Chieh Huang, Chun-Kai Huang, Sung-Hsi Huang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 15, 2021
Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV
Sung-Hsi Huang, Wei-Chieh Huang, Shu-Wen Lin, et al.
Plos One
|
September 12, 2015
Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy
Kuan-Yin Lin, Sih-Han Liao, Wen-Chun Liu, et al.
Page
of 8